Cytodyn Inc (CYDY)

[finesand]

HIV-1 Anti-infective antibodies review

Work in Progress (WIP)

So far then, competitor field is:
- Ibalizumab (IZ) targeting host CD4 receptor, TaiMed+THERF approved 2016-2018, 46% VL reduction, AEs + SAEs
- Fostemsavir targeting HIV-1 gp120 protein , ViiV Healthcare + GSK, phase 3 success: 0.79 log10 c/mL vs 0.17 log10 c/mL; p<0.0001, 18% AEs
- Pro 140 targeting host CCR5 receptor, Cytodyn, phase 3 until August 2018: > 0.5log10 p<0.01 up to >=1.8log10

Would be great if we can detail the overall competitor field.

Thanks to 01, Nuptse & Zhang

+++

"Engineering therapeutic antibodies to combat infectious diseases", Ellen K Wagner and Jennifer A Maynard, March 2018






+++

"New Drugs in the Pipeline for the Treatment of HIV: a Review",
Sep 2017